New Executive Positions at Terebellum as the Business Expands into Germany and the UK
Plans have recently been announced by the AscellaHealth Family of Companies for our Terebellum expansion into Germany and the United Kingdom.
With a focus on potential new markets, this expansion also comprises the appointment of new executive level positions, including a new vice president of market access & commercialisation and a dedicated regional director.
“Our international footprint will target opportunities to collaborate with pharmaceutical manufacturers and other stakeholders that utilise our deep payer and life sciences expertise to develop, promote and successfully drive innovative branded pharmaceutical programmes and services on a global level”, says Dea Belazi, president and CEO of AscellaHealth.
Our new services in this expanded marketplace will include:
- Supply chain logistics
- Pre-commercialisation/market access consultative services
- Unique financial pharmaceutical services, such as loan-based assistance programmes to help offset the high cost of therapies
- Focus on cell/gene therapies
- Potential distribution and/or fulfilment services throughout Germany and the UK
- Consulting services for European companies bringing business to the United States and potential synergies/partnerships with these manufacturing partners
As part of the Terebellum global leadership team, the newly appointed vice president, Floortje van Nooten PhD, has deep European payer and pharma relations expertise. She will provide strategic innovation and consultative market access support to pharma clients.
Victoria Daet MBA, who takes the role of regional director, has field based and sales-oriented and will be tasked with developing and maintaining relationships and executing strategic initiatives throughout Germany and the UK.
Belazi adds, “Worldwide expansion supports our leading market position as an industry innovator, validated by an impressive 1,556% four-year revenue increase based on organic growth and acquisitions.
“We continue to monitor drug therapy for effectiveness, compliance and adherence to treatment – the hallmarks of patient-centred care.”